Heartflow (NASDAQ:HTFL) Rating Increased to Hold at UBS Group

UBS Group upgraded shares of Heartflow (NASDAQ:HTFL) to a hold rating in a report released on Wednesday morning,Zacks reports.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company upped their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Benchmark restated a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Morgan Stanley upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Robert W. Baird set a $45.00 target price on Heartflow in a research note on Friday, August 14th. Finally, Canaccord Genuity Group boosted their price target on Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Heartflow presently has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Heartflow Trading Up 9.7%

Heartflow stock opened at $49.88 on Wednesday. Heartflow has a 12-month low of $20.13 and a 12-month high of $51.78. The firm has a market capitalization of $4.34 billion and a price-to-earnings ratio of -27.26. The firm has a 50 day moving average of $35.52 and a 200 day moving average of $30.78.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, analysts predict that Heartflow will post -0.75 EPS for the current year.

Insider Buying and Selling at Heartflow

In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total transaction of $380,099.37. Following the completion of the transaction, the insider owned 86,459 shares of the company’s stock, valued at $3,564,704.57. This represents a 9.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the transaction, the chief executive officer owned 457,935 shares of the company’s stock, valued at approximately $16,027,725. The trade was a 7.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,765 shares of company stock valued at $8,444,106 in the last 90 days. Insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

Several hedge funds have recently modified their holdings of the company. Engineers Gate Manager LP purchased a new position in shares of Heartflow in the second quarter valued at $590,000. Integrated Wealth Concepts LLC purchased a new stake in Heartflow during the second quarter valued at $53,000. Squarepoint Ops LLC lifted its position in Heartflow by 72.0% during the second quarter. Squarepoint Ops LLC now owns 87,052 shares of the company’s stock valued at $2,554,000 after purchasing an additional 36,441 shares during the last quarter. Arizona State Retirement System purchased a new position in shares of Heartflow in the 2nd quarter worth $312,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of Heartflow in the 2nd quarter worth about $1,557,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).